lazabemide,
Ro 19-6327,
Ro-19-6327,
Lazabemide hydrochloride,
103878-83-7,
Tempium,
Lazabemide HCl,
Lazabemide monohydrochloride,
UNII-PI150J9ZX1,
Ro 19-6327,
PI150J9ZX1,
Ro 19-6327/001,
N-(2-aminoethyl)-5-chloropyridine-2-carboxamide hydrochloride,
N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide monohydrochloride,
DSSTox_CID_26739,
DSSTox_RID_81868,
DSSTox_GSID_46739,
N-(2-Aminoethyl)-5-chloropicolinamide monohydrochloride,
2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-, hydrochloride,
2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-, monohydrochloride,
2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-, hydrochloride (1:1);2-Pyridinecarboxamide, N-(2-aminoethyl)-5-chloro-, hydrochloride (1:1),
CAS-103878-83-7,
NCGC00167737-01,
Pakio,
Lazabemide hydrochloride [USAN],
Tempium (TN),
AC1L4THP,
AC1Q3PNQ,
C8H10ClN3O.HCl,
SCHEMBL1230476,
CHEMBL2105029,
DTXSID4046739,
CHEBI:31766,
CTK8E9613,
JMFKTFLARGGXCC-UHFFFAOYSA-N,
Tox21_112582,
Lazabemide hydrochloride (JAN/USAN),
n-(2-aminoethyl)-5-chloropyridine-2-carboxamide hydrochloride(1:1),
AKOS024457114,
Tox21_112582_1,
RTR-000901,
NCGC00167737-02,
LS-130533,
Ro-196327001,
TR-000901,
B7064,
Ro-19-6327/001,
D01097,
J-001055,
n-(2-aminoethyl)-5-chloro-2-pyridinecarboxamide hydrochloride,
Lazabemide,
C8H10ClN3O.ClH,
Lazabemide (hydrochloride),
C8-H10-Cl-N3-O.Cl-H,
AR-1J7636,
CID163727,
112733-06-9,